Skip to content

powder for solution for infusion

DRUG7 trials

Sponsors

University College London, Erasca Inc., Philogen S.p.A., Centre Hospitalier Universitaire De Nice, Unidade Local De Saude De Sao Jose E.P.E.

Conditions

Advanced epithelial ovarianCholangiocarcinomaHeart FailureOsteoarticular infections on equipmentUnresectable and/or metastatic soft-tissue sarcoma after failure of at least two prior systemic therapy regimens.Unresectable or metastatic NRAS mutant cutaneous melanomafallopian tube or peritoneal carcinoma​ stage IA/IIA Hodgkin lymphoma

Phase 2

Phase 3

RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma
RecruitingCTIS2022-500031-37-00
University College London​ stage IA/IIA Hodgkin lymphoma
Start: 2024-04-08Target: 289Updated: 2025-06-23
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
CompletedCTIS2024-513513-12-00
Incyte Corp.Cholangiocarcinoma
Start: 2019-01-06End: 2025-06-03Target: 110Updated: 2025-07-23
A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARING THE COMBINATION OF NAPORAFENIB + TRAMETINIB TO PHYSICIAN’S CHOICE OF THERAPY (DACARBAZINE, TEMOZOLOMIDE OR TRAMETINIB MONOTHERAPY) WITH A DOSE OPTIMIZATION LEAD-IN [SEACRAFT-2]
RecruitingCTIS2024-511404-17-00
Erasca Inc.Unresectable or metastatic NRAS mutant cutaneous melanoma
Start: 2024-10-07Target: 294Updated: 2026-01-07
A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Active, not recruitingCTIS2024-519218-30-00
Canariabio Inc.Advanced epithelial ovarian, fallopian tube or peritoneal carcinoma
Start: 2021-05-26Target: 64Updated: 2025-12-01

Phase 4